Alnylam Pharmace. buy Maxi_Scalibusa
Start price
20.01.18
/
50%
€113.72
Target price
16.08.18
€336.00
Performance (%)
-27.30%
End price
16.08.18
€82.67
Summary
This prediction ended on 16.08.18 with a price of €82.67. The price of Alnylam Pharmace. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -27.30%. Maxi_Scalibusa has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -1.233% | -1.233% | 36.780% | 45.135% |
| iShares Core DAX® | 3,01 % | 1,44 % | 22,85 % | 50,83 % |
| iShares Nasdaq 100 | 3,01 % | 0,57 % | 37,06 % | 80,37 % |
| iShares Nikkei 225® | 4,14 % | 4,55 % | 53,86 % | 60,40 % |
| iShares S&P 500 | 2,38 % | 0,24 % | 29,01 % | 59,98 % |
Comments by Maxi_Scalibusa for this prediction
In the thread Alnylam Pharmace. diskutieren
(Vom Mitglied beendet)